{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:00:37Z","timestamp":1787014837199,"version":"build-2736575974"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,2,7]],"date-time":"2005-02-07T00:00:00Z","timestamp":1107734400000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2005,2]]},"abstract":"<jats:p>\n                    <jats:bold>Abstract: Background\/Aims:<\/jats:bold>\n                    Bone disease is common in patients with primary biliary cirrhosis (PBC). Our aim was to evaluate safety and efficacy of raloxifene in this population.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Nine postmenopausal women with PBC were enrolled and seven completed the study. Subjects received raloxifene 60\u2003mg daily for 1 year. Each patient on raloxifene was age\u2010matched to three controls. Liver biochemistries were monitored periodically; bone mineral density (BMD) of the lumbar spine (LS) and femoral neck (FN) was measured at baseline and at 1 year.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    No significant adverse effects were reported. Liver biochemistries remained unchanged. Baseline LS\u2010BMD was similar in the treatment group and controls [median 0.720\u2003g\/cm\n                    <jats:sup>2<\/jats:sup>\n                    (range 0.620\u20130.867) vs. 0.740\u2003g\/cm\n                    <jats:sup>2<\/jats:sup>\n                    (0.570\u20131.040),\n                    <jats:italic>P<\/jats:italic>\n                    =0.5].\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Compared with baseline, LS\u2010BMD improved significantly with 1 year of therapy [0.72\u2003g\/cm\n                    <jats:sup>2<\/jats:sup>\n                    (0.62\u20130.87) vs. 0.74\u2003g\/cm\n                    <jats:sup>2<\/jats:sup>\n                    (0.63\u20130.97),\n                    <jats:italic>P<\/jats:italic>\n                    =0.02]. FN\u2010BMD remained stable [0.53\u2003g\/cm\n                    <jats:sup>2<\/jats:sup>\n                    (0.50\u20130.60) vs. 0.54\u2003g\/cm\n                    <jats:sup>2<\/jats:sup>\n                    (0.49\u20130.63),\n                    <jats:italic>P<\/jats:italic>\n                    =0.6]. Improvement in LS BMD was seen in patients on raloxifene but not in matched controls [0.02\u2003g\/cm\n                    <jats:sup>2<\/jats:sup>\n                    (0.01\u20130.10) vs. 0.00\u2003g\/cm\n                    <jats:sup>2<\/jats:sup>\n                    (\u22120.120\u20130.040),\n                    <jats:italic>P<\/jats:italic>\n                    =0.06)]. In conclusion, raloxifene appears safe and of benefit in preventing bone loss in patients with PBC. Larger studies with longer follow\u2010up are warranted.\n                  <\/jats:p>","DOI":"10.1111\/j.1478-3231.2005.01026.x","type":"journal-article","created":{"date-parts":[[2005,2,7]],"date-time":"2005-02-07T08:34:12Z","timestamp":1107765252000},"page":"117-121","source":"Crossref","is-referenced-by-count":56,"title":["Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study"],"prefix":"10.1111","volume":"25","author":[{"given":"Cynthia","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise M.","family":"Harnois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Angulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D.","family":"Lindor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,2,7]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"316","article-title":"Bone disease in primary biliary cirrhosis","volume":"35","author":"Menon K V","year":"2001","journal-title":"independent indicators and rate of progression"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0270-9139(94)90098-1"},{"key":"e_1_2_5_4_2","first-page":"219","article-title":"Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis","volume":"113","author":"Guanabens N","year":"1997","journal-title":"preliminary results after 2 years"},{"key":"e_1_2_5_5_2","first-page":"389","article-title":"Bone disease in primary biliary cirrhosis","volume":"21","author":"Lindor K D","year":"1995","journal-title":"does ursodeoxycholic acid make a difference?"},{"key":"e_1_2_5_6_2","first-page":"878","article-title":"Etidronate for osteoporosis in primary biliary cirrhosis","volume":"33","author":"Lindor K D","year":"2000","journal-title":"a randomized trial"},{"key":"e_1_2_5_7_2","first-page":"47","article-title":"Hepatic osteodystrophy in primary biliary cirrhosis","volume":"89","author":"Crippin J S","year":"1994","journal-title":"effects of medical treatment"},{"key":"e_1_2_5_8_2","first-page":"58","article-title":"Noncardiovascular disease outcomes during 6.8 years of hormone therapy","volume":"288","author":"Hulley S","year":"2002","journal-title":"Heart and Estrogen\/progestin Replacement Study follow-up (HERS II)"},{"key":"e_1_2_5_9_2","first-page":"472A","article-title":"Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis (abstract)","volume":"30","author":"Pares A","year":"1999","journal-title":"Hepatology"},{"key":"e_1_2_5_10_2","first-page":"339","article-title":"Effects of raloxifene hydrochloride on serum markers of bone and lipid metabolism \u2013 dose\u2013response relationships (abstract)","volume":"54","author":"Draper M W","year":"1994","journal-title":"Calcif Tissue Int"},{"key":"e_1_2_5_11_2","first-page":"835","article-title":"A controlled trial of raloxifene (LY139481) HCl","volume":"11","author":"Draper M W","year":"1996","journal-title":"impact on bone turnover and serum lipid profile in healthy postmenopausal women"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199712043372301"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(83)90323-5"},{"key":"e_1_2_5_14_2","first-page":"123","article-title":"Chemoprevention of mammary carcinogenesis in the rat","volume":"88","author":"Anzano M A","year":"1996","journal-title":"combined use of raloxifene and 9-cis-retinoic acid"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.suppl_1.i1"},{"key":"e_1_2_5_16_2","first-page":"637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene","volume":"282","author":"Ettinger B","year":"1999","journal-title":"results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators"},{"key":"e_1_2_5_17_2","first-page":"3609","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis","volume":"87","author":"Delmas P D","year":"2002","journal-title":"four-year results from a randomized clinical trial"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2002.17.1.1"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980170020"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.3.8325"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(01)00685-8"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)80013-2"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.34741"},{"key":"e_1_2_5_24_2","first-page":"194","article-title":"Tamoxifen","volume":"24","author":"Reddy A","year":"2004","journal-title":"a novel treatment for primary biliary cirrhosis?"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20164"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.5.608"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.42.111901.111051"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2005.01026.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2005.01026.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2005.01026.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T09:35:17Z","timestamp":1697103317000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2005.01026.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["10.1111\/j.1478-3231.2005.01026.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2005.01026.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2]]}}}